Pds Biotechnology Quick Ratio (PDSB) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Pds Biotechnology Corp  (NASDAQ: PDSB)

Pds Biotechnology's Quick Ratio

PDSB's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 0.45 below Pds Biotechnology Corp average.

Within Major Pharmaceutical Preparations industry 395 other companies have achieved higher Quick Ratio than Pds Biotechnology in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 1200 to 2718.

Explain Quick Ratio?
How much Cash & cash equivalents PDSB´s has?
What are PDSB´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PDSB Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 7.82 % -44.44 % -44.51 % -27.32 % -26.49 %
Y / Y Cash & cash equivalent Change -82.44 % -45.82 % -35.93 % -47.34 % -44.79 %
Quick Ratio MRQ 0.45 2.14 2.83 1.97 2.78
PDSB's Total Ranking # 2718 # 1200 # 933 # 1034 # 777
Seq. Current Liabilities Change 22.36 % 7.08 % -28.89 % 15.73 % -36.95 %
Seq. Cash & cash equivalent Change -74.16 % -18.91 % 1.96 % -17.8 % -20.27 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 396
Healthcare Sector # 751
Overall Market # 2718


Quick Ratio Statistics
High Average Low
26.52 8.41 0.01
(Sep 30 2016)   (Dec 31 2018)




Financial Statements
Pds Biotechnology's Current Liabilities $ 12 Millions Visit PDSB's Balance sheet
Pds Biotechnology's Cash & cash equivalent $ 6 Millions Visit PDSB's Balance sheet
Source of PDSB's Sales Visit PDSB's Sales by Geography


Cumulative Pds Biotechnology's Quick Ratio

PDSB's Quick Ratio for the trailling 12 Months

PDSB Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -30.41 % -35.88 % -20.49 % -4.06 % 21.69 %
Y / Y Cash & cash equivalent TTM Growth -50.91 % -43.73 % -42.19 % -39.42 % -30.57 %
Quick Ratio TTM 1.77 2.4 2.38 2.33 2.51
Total Ranking TTM # 3842 # 3828 # 2981 # 3119 # 2716
Seq. Current Liabilities TTM Growth 2.03 % -15.43 % -12.63 % -7.69 % -5.98 %
Seq. Cash & cash equivalent TTM Growth -24.69 % -14.68 % -10.72 % -14.42 % -13.67 %

Quick ratio ranking by company, industry and sector >> Back to PDSB Financial Strength Comparisons >> Go to Compare PDSB Quick Ratio to its Competitors

On the trailing twelve months basis Due to growth in Current Liabilities in the Q2 2026 to $12.38 millions, cumulative Quick Ratio decreased to 1.77 below the Pds Biotechnology Corp average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 432 other companies have achieved higher Quick Ratio than Pds Biotechnology. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 3828 to 3842.

Explain Quick Ratio?
How much Cash & cash equivalents PDSB´s has?
What are PDSB´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 433
Healthcare Sector # 885
Within the Market # 3842


trailing twelve months Quick Ratio Statistics
High Average Low
18.55 8.27 1.77
(Dec 31 2016)   (Jun 30 2026)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Petros Pharmaceuticals inc   1.23 $ 3.489  Millions$ 2.845  Millions
Nature s Sunshine Products inc   1.20 $ 82.503  Millions$ 68.745  Millions
Phathom Pharmaceuticals Inc   1.19 $ 182.478  Millions$ 153.777  Millions
Compass Pathways Plc  1.18 $ 433.720  Millions$ 367.285  Millions
Geovax Labs Inc   1.17 $ 3.163  Millions$ 2.712  Millions
Actuate Therapeutics Inc   1.16 $ 4.426  Millions$ 3.805  Millions
Apimeds Pharmaceuticals US, Inc.  1.16 $ 8.278  Millions$ 7.166  Millions
Emergent Biosolutions Inc   1.14 $ 139.700  Millions$ 122.800  Millions
Turn Therapeutics Inc   1.14 $ 9.958  Millions$ 8.764  Millions
Ionis Pharmaceuticals Inc   1.11 $ 350.065  Millions$ 315.638  Millions
Oramed Pharmaceuticals Inc  1.00 $ 16.091  Millions$ 16.044  Millions
Inmed Pharmaceuticals Inc  1.00 $ 2.240  Millions$ 2.235  Millions
Nkarta Inc   1.00 $ 24.958  Millions$ 24.924  Millions
Inovio Pharmaceuticals Inc   1.00 $ 36.700  Millions$ 36.678  Millions
Jazz Pharmaceuticals Plc  0.98 $ 2,199.800  Millions$ 2,239.400  Millions
Akebia Therapeutics Inc   0.97 $ 155.548  Millions$ 160.865  Millions
Syndax Pharmaceuticals Inc   0.95 $ 342.883  Millions$ 360.284  Millions
Nurix Therapeutics Inc   0.94 $ 67.840  Millions$ 72.020  Millions
Theriva Biologics inc   0.94 $ 11.337  Millions$ 12.111  Millions
Geron Corporation  0.92 $ 64.781  Millions$ 70.331  Millions
Zomedica Corp   0.84 $ 7.605  Millions$ 9.002  Millions
Cocrystal Pharma Inc   0.83 $ 2.169  Millions$ 2.616  Millions
Harrow Inc   0.82 $ 83.889  Millions$ 102.171  Millions
Cue Biopharma Inc   0.82 $ 17.414  Millions$ 21.218  Millions
Zoetis Inc   0.81 $ 1,676.000  Millions$ 2,061.000  Millions
Organogenesis Holdings Inc   0.81 $ 46.097  Millions$ 56.963  Millions
Bridgebio Pharma Inc   0.81 $ 720.160  Millions$ 890.648  Millions
Nrx Pharmaceuticals Inc   0.79 $ 26.686  Millions$ 33.874  Millions
Oncolytics Biotech Inc   0.79 $ 4.115  Millions$ 5.225  Millions
Moleculin Biotech Inc   0.78 $ 7.262  Millions$ 9.313  Millions

Date modified: 2026-09-08T19:57:38+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.